Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

NEW YORK, April 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

http://www.reportlinker.com/p01160236/Therapeutic-Cancer-Vaccines-Market-to-2019---Pipeline-Indicates-Safer-Treatments-and-Extended-Patient-Survival-though-High-Prices-May-Limit-Uptake.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake". There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬–resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011. Over the forecast period, numerous vaccines are anticipated to be approved over a range of indications including the commonly diagnosed lung and colorectal cancer types. All of these vaccines have been shown to improve patient survival, some by a few months, others by years. The high anticipated price tag of these vaccines will be a barrier of market growth. However, due to the fact that numerous vaccines are anticipated to be approved across a range of highly diagnosed indications, GBI Research believes the global market does have the potential to grow to a value of $7.8 billion by 2019.

Scope

- The report analyzes treatment usage patterns, variation in vaccine type and pipeline and market forecasts across indications for cancer vaccines.
- A brief introduction into cancer, its relation with the immune system, and a detailed outline of the 8 different types of cancer vaccines being developed, including their strengths and weaknesses.
- An analysis of Provenge, the only currently marketed therapeutic cancer vaccines, including recent sales figures and potential future competitors of Provenge.
- Comprehensive reviews of the pipeline for therapeutic cancer vaccines with individual analyses on the most heavily researched and most common cancers of melanoma, breast, prostate, colorectal, stomach and Non-small-cell lung cancer. The analyses include the phase distribution, the most common type of vaccine and most frequently observed molecular target for each indication.
- A statistical analysis of clinical trial duration and size by phase and by vaccine type.
- An in depth forecast model for each indication for which a vaccine is anticipated to be approved throughout the forecast period. Each model is based on the anticipated market performance of the vaccines to be approved for that indication.
- A detailed discussion of the drivers and barriers for this novel market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Understand the variation in the types of therapeutic cancer vaccines, and the strength and weaknesses of each form.
- Understand the vast scope of the pipeline, including which vaccine types and molecular targets are generating the most interest.
- Observe the trends in clinical trial duration and size amongst Phases and vaccine types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for therapeutic cancer vaccines.
- Observe the shift in clinical trial endpoints with Phase, and use this data to potentially influence any future developmental programs.
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the therapeutic cancer vaccines market.

Table of Contents

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Cancer Epidemiology 11
2.2 Disease Initiation and Propagation 11
2.3 Symptoms 12
2.3.1 Symptoms of Lung Cancer 12
2.3.2 Symptoms of Prostate Cancer 12
2.3.3 Symptoms of Colorectal Cancer 12
2.3.4 Symptoms of Breast Cancer 12
2.3.5 Symptoms of Melanoma 12
2.3.6 Symptoms of Stomach Cancer 12
2.4 Current Treatment and Management 13
2.4.1 Active Surveillance or the 'Wait-and See' Approach 13
2.4.2 Surgery 13
2.4.3 Radiation Therapy 13
2.4.4 Chemotherapy 13
2.4.5 Targeted Therapy 13
2.4.6 Hormone Therapy 14
2.4.7 Immunotherapy 14
2.5 Virally Induced Cancers and Prophylactic Vaccines 14
2.6 Cancer, the Immune system and Therapeutic Vaccines 15
2.6.1 Mechanisms of Immune System Evasion 15
2.6.2 Mechanisms of Immune System Disabling 15
2.7 Why Develop Therapeutic Cancer Vaccines? 16
2.8 Types of Therapeutic Cancer Vaccine 16
2.8.1 Anti-Idiotype Vaccines 16
2.8.2 Whole-Cell-Derived Vaccines 16
2.8.3 Cellular Immunotherapy 17
2.8.4 Antigen-Based Vaccines 17
2.8.5 DNA-Based Vaccines 17
2.8.6 Vector-Based (Microorganism-Facilitated) Vaccines 17
2.8.7 Oncolytic Virus Vaccines 18
2.8.8 Adjuvants 18
3 Marketed Products 19
3.1 Provenge – an Autologous Cellular Immunotherapy Vaccine for the Treatment of Hormone-Refractory Prostate Cancer 19
3.1.1 Overview 19
3.1.2 Mechanism of Action and Molecular Target 19
3.1.3 Formulation and Dosing 19
3.1.4 Provenge within the Clinical Landscape for Prostate Cancer 19
3.1.5 Company Profile and Patent Expiry 20
3.2 Recent Sales and Commercialization of Provenge 20
3.3 Current and Future Market Competitors for Provenge 22
4 Product Pipeline 24
4.1 Pipeline Overview 24
4.1.1 Developmental Pipeline of all Major Indications 27
4.1.2 Clinical Trials 36
4.1.3 Clinical Trial Failure 41
4.1.4 Key Companies Developing Cancer Vaccines 44
4.1.5 Promising Drugs in the Developmental Pipeline 45
5 Forecasting 52
5.1 Therapeutic Cancer Vaccines Market to 2019 – Global 52
5.1.1 Treatment Usage Patterns 53
5.1.2 Annual Cost of Treatment 53
5.2 Colorectal Cancer 53
5.2.1 Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns 53
5.2.2 Annual Cost of Therapy 54
5.2.3 Market Size 56
5.3 Glioblastoma Multiforme 58
5.3.1 Emerging Cancer Vaccines and their Treatment Usage Patterns 58
5.3.2 Annual Cost of Therapy 59
5.3.3 Market Size 60
5.4 Lymphoma 62
5.4.1 Emerging Cancer Vaccines for Lymphoma and their Treatment Usage Patterns 62
5.4.2 Annual Cost of Therapy 62
5.4.3 Market Revenues 64
5.5 Melanoma 66
5.5.1 Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns 66
5.5.2 Annual Cost of Therapy 67
5.5.3 Market Size 69
5.6 Non-Small-Cell Lung Cancer 71
5.6.1 Emerging Vaccines and Treatment Usage Patterns 71
5.6.2 Annual Cost of Therapy 71
5.6.3 Market Size 73
5.7 Pancreatic Cancer 74
5.7.1 Emerging Cancer Vaccines and their Market Impact 74
5.7.2 Annual Cost of Therapy 74
5.7.3 Market Revenues 76
5.8 Prostate Cancer 78
5.8.1 Treatment Usage Patterns and the Impact of Emerging Vaccines 78
5.8.2 Annual Cost of Treatment 78
5.8.3 Market Revenues 80
5.9 Drivers and Barriers for Therapeutic Cancer Vaccines Market 82
5.9.1 Drivers 82
5.9.2 Barriers 83
6 Appendix 85
6.1 Provenge Clinical Trial Titles (Table 3) 85
6.2 Predicated Annual Cost of Therapy 85
6.2.1 Colon Cancer 85
6.2.2 Glioblastoma Multiforme 85
6.2.3 Lymphoma 86
6.2.4 Melanoma 86
6.2.5 Non-Small-Cell Lung Cancer 87
6.2.6 Pancreatic Cancer 87
6.2.7 Prostate Cancer 88
6.3 Predicted Market Forecasts 88
6.3.1 Colon Cancer 88
6.3.2 Glioblastoma Multiforme 89
6.3.3 Lymphoma 89
6.3.4 Melanoma 90
6.3.5 Non-Small-Cell Lung Cancer 90
6.3.6 Pancreatic Cancer 91
6.3.7 Prostate 91
6.4 All Pipeline Drugs by Phase 92
6.4.1 Discovery 92
6.4.2 Preclinical 93
6.4.3 IND-Filed and Phase 0 95
6.4.4 Phase I 96
6.4.5 Phase II 101
6.4.6 Phase III 105
6.5 Market Definitions 106
6.6 Abbreviations 107
6.7 Sources 108
6.8 Research Methodology 111
6.8.1 Coverage 111
6.8.2 Secondary Research 111
6.8.3 Primary Research 112
6.8.4 Therapeutic Landscape 112
6.8.5 Epidemiology-Based Forecasting 112
6.8.6 Analogous Forecasting Methodology 113
6.8.7 Diseased Population 113
6.8.8 Prescription Population 113
6.9 Market Size by Geography 114
6.9.1 Forecasting Model for Therapeutic Areas 114
6.10 Geographical Landscape 115
6.11 Pipeline Analysis 115
6.12 Expert Panel Validation 115
6.13 Contact Us 115
6.14 Disclaimer 115

List of Tables

Table 1: Therapeutic Cancer Vaccines Market, Infectious Agents and Associated Cancer(s), 2011 14
Table 2: Dendreon Corporation, Global, Provenge, Revenue ($m), 2010–2011 20
Table 3: Therapeutic Cancer Vaccines Market, Provenge, Clinical Trials upto 2012 21
Table 4: Therapeutic Cancer Vaccines Market, Safety, Efficacy and Annual Cost of Therapy of Provenge, DCVax-Prostate and Prostvac, 2013-2019 22
Table 5: Therapeutic Cancer Vaccines Market, Global, Common Molecular Targets, 2013 26
Table 6: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, 1998–2012 42
Table 7: Therapeutic Cancer Vaccines Market, Global, Key Companies, 2013 44
Table 8: Therapeutic Cancer Vaccines Market, Global, Allovectin, Phase II Clinical Trial Results, up to 2012 45
Table 9: Therapeutic Cancer Vaccines Market, Global, Lucanix, Phase II Clinical Trial Results, 2006 46
Table 10: Therapeutic Cancer Vaccines Market, Global, Safety and Efficacy of Common Adjuvant Treatment Regimes for Glioblastoma Multiforme 47
Table 11: Therapeutic Cancer Vaccines Market, Global, Cost, Safety and Efficacy of Potential Adjuvant Chemotherapy Regimens for Stage II Colon Cancer 54
Table 12: Therapeutic Cancer Vaccines Market, Global, Safety and Efficacy of Adjuvant Chemotherapy Regimens for Glioblastoma Multiforme 58
Table 13: Therapeutic Cancer Vaccines Market, Global, Common Metastatic Melanoma Treatments and Vaccines Expected to be Approved, Safety and Efficacy, 67
Table 14: Colon Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2015–2019 85
Table 15: Glioblastoma Multiforme, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019 85
Table 16: Lymphoma, Global, Predicted Annual Cost of Therapy ($'000), 2013-2019 86
Table 17: Melanoma, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019 86
Table 18: Non-Small-Cell Lung Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2014-2018 87
Table 19: Pancreatic Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019 87
Table 20: Prostate Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2013-2019 88
Table 21: Colon Cancer, Global, Predicted Market Revenues ($m), 2015-2019 88
Table 22: Glioblastoma Multiforme, Global, Predicted Market Revenues ($m), 2015-2019 89
Table 23: Lymphoma, Global, Predicted Market Revenues ($m), 2013-2019 89
Table 24: Melanoma, Global, Predicted Market Revenues ($m), 2015-2019 90
Table 25: Non-Small-Cell Lung Cancer, Global, Predicted Market Revenues ($m), 2014-2019 90
Table 26: Pancreatic Cancer, Global, Predicted Market Revenues ($m), 2015-2019 91
Table 27: Prostate Cancer, Global, Predicted Market Revenues ($m), 2013-2019 91
Table 28: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Discovery Phase 92
Table 29: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Preclinical Phase 93
Table 30: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase 0 or IND-Filed 95
Table 31: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase I 96
Table 32: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase II 101
Table 33: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase III 105

List of Figures

Figure 1: Therapeutic Cancer Vaccines Market, Global, Common Cancers and Incidence Rates, 2008 11
Figure 2: Therapeutic Cancer Vaccines Market, Global, Pipeline Overview (%), 2013 25
Figure 3: Therapeutic Cancer Vaccines Market, Global, Pipeline by Indication, Incidence by Indication (million), 2013 27
Figure 4: Therapeutic Cancer Vaccines Market, Global, Lung Cancer, Pipeline Overview, 2013 28
Figure 5: Therapeutic Cancer Vaccines Market, Globa, Breast Cancer, Pipeline Overview, 2013 30
Figure 6: Therapeutic Cancer Vaccines Market, Global, Colorectal Cancer, Pipeline Overview, 2013 31
Figure 7: Therapeutic Cancer Vaccines Market, Global, Stomach Cancer, Pipeline Overview, 2013 32
Figure 8: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Pipeline Overview, 2013 34
Figure 9: Therapeutic Cancer Vaccines Market, Global, Melanoma, Pipeline Overview, 2012 35
Figure 10: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Duration (months), 1998–2012 36
Figure 11: Therapeutic Cancer Vaccines Market, Global, Cumulative Clinical Trial Duration (months), 1998–2012 37
Figure 12: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Size by Phase and Vaccine Type, 1998–2012 38
Figure 13: Therapeutic Cancer Vaccines Market, Global, Primary and Secondary Endpoints, Pipeline, 1998–2012 40
Figure 14: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Failure, Pass and Inferred Pass Rates, 2006–2012 41
Figure 15: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Failure, 1998–2012 43
Figure 16: Therapeutic Cancer Vaccines Market, Global, Revenue Forecast ($bn), 2013–2019 52
Figure 17: Therapeutic Cancer Vaccines Market, Global, Colon Cancer, Target Market ('000) and Annual Cost of Therapy ($'000) Forecast, 2015–2019 55
Figure 18: Therapeutic Cancer Vaccines Market, Global, Colon Cancer, Revenue Forecast ($m), 2015–2019 57
Figure 19: Therapeutic Cancer Vaccines Market, Global, Glioblastoma Multiforme, Target Market ('000) and Annual Cost of Therapy ($'000) Forecast, 2015–2019 59
Figure 20: Therapeutic Cancer Vaccines Market, Global, Glioblastoma Multiforme, Revenue Forecast ($m), 2015–2019 61
Figure 21: Therapeutic Cancer Vaccines Market, Global, Lymphoma, Annual Cost of Therapy ($'000) and Target Market ('000), 2013–2019 63
Figure 22: Therapeutic Cancer Vaccines Market, Global, Lymphoma, Revenue Forecast ($m), 2013–2019 65
Figure 23: Therapeutic Cancer Vaccines Market, Global, Melanoma, Annual Cost of Therapy ($'000) and Target Market ('000), 2015–2019 68
Figure 24: Therapeutic Cancer Vaccines Market, Global, Melanoma, Revenue Forecast ($m), 2015–2019 70
Figure 25: Therapeutic Cancer Vaccines Market, Global, Non-Small-Cell Lung Cancer, Annual Cost of Therapy ($'000) and Target Market ('000), 2014–2019 72
Figure 26: Therapeutic Cancer Vaccines Market, Global, Non-Small-Cell Lung Cancer, Annual Cost of Therapy ($'000) and Target Market ('000), 2014–2019 73
Figure 27: Therapeutic Cancer Vaccines Market, Global, Pancreatic Cancer, Annual Cost of Treatment ($'000) and Target Market ('000), 2015–2019 75
Figure 28: Therapeutic Cancer Vaccines Market, Global, Pancreatic Cancer, Revenue Forecast ($m), 2015–2019 77
Figure 29: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Annual Cost of Treatment ($'000) and Target Market ('000), 2013–2019 79
Figure 30: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Revenue Forecast ($m), 2013–2019 81
Figure 31: GBI Research Market Forecasting Model 114

To order this report:
Drug_and_Medication Industry: Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker